Citadel Advisors’s CERo Therapeutics CERO Stock Holding History

Citadel Advisors’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-811	Closed	-$11.8K	–	15481
2025 Q1	$11.8K	Buy	+811	New	+$32K	﹤0.01%	13470
2022 Q2	–	Sell	-375	Closed	-$7.5M	–	14285
2022 Q1	$7.5M	Hold	375	–	–	﹤0.01%	3439
2021 Q4	$7.43M	Buy	+375	New	+$7.44M	﹤0.01%	3606

Other funds holding CERO

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's CERO Position: Q2 2025 in Review

Citadel Advisors sold out of CERo Therapeutics (CERO) in Q2 2025, closing a stake of 811 shares — an estimated $11.8K sold.

Citadel Advisors first reported a position in CERO in Q4 2021 and held it in 3 quarters. The position peaked at $7.5M in Q1 2022. 8 funds tracked by Wall St. Rank hold CERO as of Q2 2025.

Citadel Advisors reported no remaining CERo Therapeutics position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 811 CERo Therapeutics shares in Q2 2025, an estimated $11.8K.
Citadel Advisors first reported a position in CERo Therapeutics in Q4 2021 and held it in 3 quarters.
Citadel Advisors's CERo Therapeutics position peaked at $7.5M in Q1 2022.
8 funds tracked by Wall St. Rank held CERo Therapeutics as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.